Thrombolysis and RIPC in Acute Ischemic Stroke (tripcais)
Acute Ischemic Stroke, Cerebral Embolism and Thrombosis
About this trial
This is an interventional treatment trial for Acute Ischemic Stroke, Cerebral Embolism and Thrombosis
Eligibility Criteria
Inclusion Criteria:
- In accordance with the Guideline of Thrombolysis in Acute Ischemic Stroke and accomplish intravenous thrombolytic therapy using alteplase;
- The consciousness of patients are conscious,somnolence,confusion and stupor,can comply better with the RIPC treatment;
- Acute ischemic stroke confirmed by cranial CT/MRI;
- Provision of written informed consent.
Exclusion criteria:
- History of cerebral embolism,cerebral hemorrhage, brain tumor, brain trauma or other brain lesion;
- Severe cardiac, liver, or kidney disease, malignancy, systemic organ dysfunction;
- Blood pressure <90/60 mmHg or >200/110 mmHg after treatment;
- Dementia or mental illness;
- History of major surgery or trauma 4 weeks prior to admission;
- Failure to provide informed consent.
Sites / Locations
- The First Affiliated Hospital of Xi'an Jiaotong University
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
RIPC
Blank control group(BC)
Remote ischemic postconditioning(RIPC):Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.